

C. William (“Bill”) Wester, MD, MPH

Curriculum Vitae

Work

Vanderbilt Institute for Global Health (VIGH)
2525 West End Avenue, Suite 750
Nashville, TN 37302-1738
william.wester@vumc.org
Office: 615-875-0145

Home

404 Hunterwood Court
Brentwood, TN 37027
cwwester@gmail.com
Mobile: 615-715-4706

ORCID ID: <http://orcid.org/0000-0002-8375-3926>

Profile

- Accomplished Academic Infectious Disease physician with 20+ years of mentoring, program development/oversight and clinical research experience.
- Focus of my present research includes long-term HIV complications with a focus on implementation science and HIV-associated kidney disease and other non-communicable diseases (NCDs) in resource-constrained settings of the world.
- Track record of developing and implementing innovative HIV service programs, building relationships and partnerships with Ministry of Health, other academic and clinical implementing partners, and non-governmental organizations.
- Proven ability to direct large global health programs that serve the needs of vulnerable populations, conduct program evaluations/operational research and implement practical solutions.
- Proven track record of successful mentoring (all levels of trainees and now expanding to junior/mid-level faculty interested in academic careers in global health)
- Successful in obtaining extramural grant funding to conduct research/evaluations (for program improvement) including NIH, CDC/PEPFAR, and USAID grants.

- | | |
|---|---|
| ✓ Passion for excellence and achievement | ✓ Strong interpersonal and communication skills |
| ✓ Research (Implementation Science & clinical trials) | ✓ Program & Project Leadership |
| ✓ Program Design & Implementation | ✓ Proven track record of extramural funding |
| ✓ Global Health Experience | ✓ Grant & Report Writing |
| ✓ Numerous peer-reviewed publications | ✓ Proven History of Successful Mentoring |
| ✓ Program Evaluation | ✓ Presentations and Public Speaking |
| ✓ Clinical Care Provider | ✓ 10+ years of Veteran’s Hospital experience |

Education and Training

1987	BA, Biology and Economics, Bowdoin College, Brunswick, ME
1991	MD, Geisel School of Medicine at Dartmouth, Hanover, NH
1991-1994	Residency in Internal Medicine, Rush University Medical Center, Chicago, IL
1994-1995	Chief Resident, Department of Medicine, Rush University Medical Center, Chicago, IL
1996-1998	Clinical Fellow in Infectious Diseases, Rush University Medical Center, Chicago, IL
2010	MPH, Quantitative Methods, Harvard T.H. Chan School of Public Health, Boston, MA

Positions

Current (Vanderbilt University Medical Center; VUMC; Nashville, TN)

2018 Associate Director, Global Health Faculty Development
2018- Professor, Department of Medicine (effective 11/1/2018)
2008- Member, Tennessee Center for AIDS Research
2014- Co-Director, Global Health Pathway, Internal Medicine Residency
2016- Affiliated Faculty, Center for Clinical Quality and Implementation Research (CCQIR)
2012- Affiliated Faculty, Vanderbilt Tuberculosis Center
2016- Center for Health Services Research (HSR)
2019- Associate Director, Global Health Faculty Development

Current (Vanderbilt University School of Medicine; VUSM)

2020- Member, Admissions Committee (formerly Executive Admissions Committee)

Previous (Harvard T.H. Chan School of Public Health)

2000-2020 Research Associate, Department of Immunology & Infectious Diseases (IID)

Previous (Vanderbilt University Medical Center, VUMC)

2014-2018 Associate Professor, Department of Medicine
2008-2014 Assistant Professor, Department of Medicine

Previous (Vanderbilt University School of Medicine; VUSM)

2015-2019 Member, Interview Review Subcommittee (IRS)
2015-2019 Portfolio Coach (cohort of 10 medical students)

Previous (Harvard T.H. Chan School of Public Health; Botswana Harvard AIDS Institute Partnership)

2000-2008 Site Leader / Site Principal Investigator of the Gaborone and Molepolole Clinical Research Sites (CRSs); Adult AIDS Clinical Trials Group (ACTG) Clinical Trials Unit (CTU)
2000-2008 Co-Study Coordinator / Site Leader / Site PI; Adult Antiretroviral Treatment and Drug Resistance (“*Tshepo*”) study/randomized controlled trial (“*Secure the Future*” foundation)

Previous (Rush Medical College)

1994-1998 Clinical Instructor
1998-2000 Assistant Professor of Medicine

Medical Staff Appointments

1995-1996 Attending Physician, Vencor Hospital, Northlake, IL
1998-2000 Attending Physician, Division of Infectious Diseases, John H. Stroger, Jr. Hospital of Cook County

Medical Licensure

2008- Tennessee, # 44131

2008- DEA, # FW1060805

Board Certifications

1995 American Board of Internal Medicine, Diplomate in Internal Medicine, # 157770
(valid thru 12/31/2027)

1998 American Board of Internal Medicine, Diplomate in Infectious Diseases, # 157770
(valid thru 12/31/2029)

Honors and Awards

1991-1994 Outstanding Medical Resident Teaching Award
(Six Consecutive and Maximum Eligible Terms)
Rush University Medical Center, Chicago, IL

1992 Outstanding Internal Medicine Resident Annual Award
Rush University Medical Center, Chicago, IL

1994 Full Scholarship Recipient
SHEA-CDC Training Course (Denver, CO)

1994 Aesculapius Award (Outstanding Medical Resident)
Rush Medical College, Chicago, IL

2010 William Schaffner Teaching Award Recipient in Infectious Diseases
Vanderbilt University Medical Center
Division of Infectious Diseases
Chosen by Infectious Disease fellows

2010 Teacher Recognition Award
Vanderbilt University School of Medicine
Chosen by Medical Students

2016 Selected as Mid-Career Academician with evident leadership ability
within the Vanderbilt University Medical Center, Department of Medicine
To participate in year-long Mid-Career Leadership Program (January-December 2017)

Scientific and Professional Organizations

2007-2008 Member
Clinical Management of HIV and AIDS Committee (National Guidelines Committee)
Ministry of Health, Botswana

2008-2011 Member
Optimization of Co-Infection and Co-Morbidity Management (OpMAN) Committee Adult AIDS
Clinical Trials Group (ACTG)

2010- Member
Program Evaluation Committee/Fellowship Oversight Committee (FPPC)

Vanderbilt University Medical Center
Division of Infectious Diseases

2011-2016 Member
Education Committee
Vanderbilt University School of Medicine
Division of Infectious Diseases

2011-2014 Member
Co-Infections and Malignancies Sub-Committee
Adult AIDS Clinical Trials Group (ACTG)

2011-2016 Co-Course Director
Grand Rounds
Vanderbilt University Medical Center
Division of Infectious Diseases

2011-2014 Member
Curriculum 2.0 Global Health curriculum development
Vanderbilt University School of Medicine

2012-2015 Member
HIV & Aging Inter-CFAR Working Group/Committee
Centers for AIDS Research (CFAR)

2012-2013 Member
Chairperson Search Committee
Vanderbilt University School of Medicine
Department of Medicine, Division of Infectious Diseases

2014- Co-Chair
International epidemiologic Databases to Evaluate AIDS (IeDEA) consortium
Site Assessment Working Group

2014-2017 Member
International epidemiologic Databases to Evaluate AIDS (IeDEA) consortium
Clinical Outcomes Working Group, including member of Renal Outcomes sub-group

2016- Faculty Member
Center for Clinical Quality and Implementation Research (CCQIR) at Vanderbilt
Vanderbilt University Medical Center

2017- Member of NIDDK Innovative Science research group
Annual meetings / research progress presentations (1 of 10 researchers in group)

2020- Member
COVID-19 Pharmacotherapeutic Subcommittee
Vanderbilt University Medical Center

Editorial Boards

2017- *PLOS ONE* Editorial Board

Reviewer — Journal manuscripts

AIDS Research and Human Retroviruses
Journal of Infectious Diseases
The American Journal of Tropical Medicine and Hygiene
The Lancet
Expert Review of Anti-Infective Therapy/Future Science Group
JAMA
PLoS ONE
BMC Infectious Diseases
Journal of AIDS and HIV Research
Current HIV Research

Reviewer – Grant Applications (including Extramural NIH Study Sections)

2011 *Creative and Novel Ideas in HIV Research (CNIHR) Developmental Grant Program –* Collaboration between the International AIDS Society, University of Washington (UW) University of Alabama Center for AIDS Research (CFAR), and Institute of Translational Health Sciences, **Role:** Primary/Secondary reviewer

2016- *Tennessee Center for AIDS Research (Tennessee CFAR) Research Developmental Core awards,* **Role:** Primary/Secondary reviewer

2016 NIH (NIDDK), Center for Scientific Review Special Emphasis Panel (HIV-Associated Kidney Disease); Center for Scientific Review; ZRG1 BDCN-S (02) M, *Elucidating HIV and HIV-treatment Associated Metabolic/Endocrine Dysfunction,* **Role:** Primary/Secondary reviewer

2016- *EDGE Scholars grant review* (internal R21, R01, K01, K08, and K23 grant review for early career researchers), Office for Clinical & Translational Scientist Development (OCTSD) Vanderbilt University Medical Center, **Role:** Primary/Secondary reviewer

2017 NIH (NIAID), 2017/01 ZRG1 AARR-J (56) R - PAR Panel: *Multidisciplinary Studies of HIV and Viral Hepatitis Co-Infection,* **Role:** Primary/Secondary reviewer

2017 NIH (NICHD), Special Emphasis Panel, *NICHD International and Domestic Pediatric and Maternal HIV and Other High Priority Infectious Disease Diseases Data Coordinating Center,* **Role:** Primary/Secondary reviewer

2018 *Global PhD Programme in Public Health Sciences of SSPH (Global P₃HS Program)* Swiss School of Public Health, Bern, Switzerland, **Role:** Primary/Secondary reviewer, member of International Review panel

2019 NIH/CSR; Special Emphasis Panel/Scientific Review Group 2019/05 ICP1; Fogarty K43 and D43 applications; **Role:** Primary/Secondary reviewer (April 2nd-3rd, 2019)

2020 NIH (Fogarty International Center), ZRG1 BDCN-L55; Fogarty D43 grant applications; **Role:** Chair and Primary/Secondary Reviewer (April 2nd, 2020)

NIH (NICHD), ZRG1 AARR-J 40 - RFA-HD-20-002: Pediatric HIV/AIDS Cohort Study; **Role:** Primary/Secondary Reviewer (April 22nd, 2020)

NIH (NIAID), ZAI1 EC-D (J2) 1: Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11 Clinical Trial Not Allowed); **Role:** Chair and Primary/Secondary Reviewer (October 30th, 2020)

2021 NIH / ZRG1 PSE-L (55) R; PAR-18-901: Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award; Primary Reviewer (April 8th, 2021)

Select Presentations (past 3 years)

- October 20, 2020 Invited lecture/seminar to Mozambique Ministry of Health, Mozambique National Institute of Health (INS), CDC Mozambique leadership, WHO, USAID, ICAP, EGPAF, Arial, CCS; given with Dr. Buddy Creech (Director of VUMC Vaccine Research Program); entitled *"COVID-10 Vaccine Landscape / Operational Considerations for Vaccine Roll-Out."*
- July 18, 2020 Invited lecture to Uganda rural health chapter, lectured to involve chapter undergraduate students (from multiple universities including U. Michigan, Washington University, St. Louis, Williams College, Notre Dame University, and University of Chicago) plus Uganda global health experience leadership; entitled *"Career in Global Health: Assisting Sub Saharan African Countries in their HIV/AIDS Responses"*
- April 27, 2020 Vanderbilt Institute for Global Health (VIGH), Grand Rounds presentation, *"Mozambique PEPFAR Update"*; Presented programmatic data from our ongoing funded U01 (CDC/PEPFAR-funded cooperative agreement # GGH001943); which I am the Contact PI/Project Director
- September 6, 2019 VUMC Department of Medicine Annual Scientific Advisory Board (SAB) meeting; invited presentation (invited by Dr. Nancy Brown; Chair of Medicine). *"Improving HIV Continuum of Care Outcomes in Rural Mozambique"*
- May 17, 2019 Witwatersrand University, Renal Genetics Collaborative Research Group (including collaborators from the NIH), Johannesburg, South Africa, *"Renal Risk Reduction (R3) RCT in Nigeria"* update/new possible grant/scientific evaluation directions
- November 12, 2018 Tennessee CFAR Works in Progress presentation, *"Renal Risk Reduction (R3) RCT in Nigeria"* update/future directions, Vanderbilt University Medical Center
- March 19, 2018 Vanderbilt Institute for Global Health (VIGH), Grand Rounds presentation, *"Renal risk reduction in HIV positive adults in Nigeria"* Presented data from our newly funded R01 turned U01 (cooperative agreement/randomized controlled trial (RCT) with NIDDK); which I am the Contact PI
- March 8, 2018 Invited speaker/lecture entitled *"Non communicable disease (NCD) site survey"* (including role as discussion chair for entire NCD section), at March 2018 *International epidemiologic Databases to Evaluate AIDS (leDEA) consortium all-day Investigator's*

meeting (with collaborators from NIH institutes): following 25th CROI conference, Boston, MA

February 1, 2018

"Bringing HIV Care to Rural Mozambique: Update and Future Directions."
Vanderbilt University School of Medicine, Nashville, TN
Division of Infectious Diseases Grand Rounds

January 22 & 23, 2017

Invited plenary lecture; *"Chronic Consequences of Global Infectious Diseases"* Conference, *"Site Capacity to Screen for and Manage NCDs in HIV Care and Treatment Clinics within the International epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium: Preliminary Data and Future Directions"* NIH/Fogarty, talk entitled *"Site Capacity to Screen for and Manage NCDs in HIV Care and Treatment Clinics within the IeDEA consortium: Preliminary Data and Future Directions"*
Vanderbilt University Medical Center

September 25, 2017

Invited plenary lecture, *"Global Health at Vanderbilt: The Impact of an Institute without Walls"*, Sten H. Vermund symposium. Talk entitled *"VIGH Service Initiatives"*
Vanderbilt University Medical Center

November 21, 2016

"Scale-Up of Comprehensive HIV/AIDS Services in Rural Mozambique: Avante"

Teaching Activities

Lectures

2000-2008

Guest Lecturer
Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP); 50+ Lectures

2000-2008

Senior Lecturer
National HIV/AIDS training program for all Health Professionals in Botswana (physicians, nurses, counselors, and pharmacy staff); 30+ Lectures

November 2015

Senior Lecturer
Vanderbilt University/Friends in Global Health, Alto Molocue district hospital, Mozambique; led 2-day training (theoretical plus practical) of 13 health professionals (Clinicians, medical technicians, plus pharmacy staff) on Kaposi's sarcoma (establishing them and their hospital as a center of excellence for the province)

2015-

Director/Primary Instructor
Lead journal club discussions for all medical doctors plus senior technical staff working for our CDC-PEPFAR funded grant in rural Mozambique

Courses

2010-

Guest Lecturer

Global HIV/AIDS: Case Presentations from Sub-Saharan Africa
Vanderbilt University Medical Center
Division of Infectious Diseases
Infectious Diseases Fellowship Program Core Curriculum

- 2010-2017 Guest Lecturer
Travel Medicine, Vanderbilt University School of Medicine
Immersion phase (Research) Core Curriculum
- 2010- Course Director/Primary Instructor
Case Studies in Tropical Diseases (SPR.AS.MHS 316.01; IHGM 5249) (**NOTE:** This course is now taught completely on-line through taped/posted lectures with live course thread), Vanderbilt University School of Medicine
- 2010-2013 Group Facilitator/Primary Discussant
Vanderbilt Institute for Global Health (VIGH)
Health Team Program for HIV Prevention & Care in Nigeria
(Bi-Weekly HIV Clinical Case Discussions and Journal Club facilitation – via conference call); 30+ Calls
- 2011-2017 Guest Lecturer
Prevention and Treatment Interventions in Resource Limited Environments
Vanderbilt University School of Medicine
Foundation of Global Health Certificate Course
- 2017- Co-Course Director
Global Health Case Conference: live webinar focused on clinical case review/discussion with healthcare providers in western Kenya (Lwala Community Alliance)
- 2020- Course Co-Director/Primary Instructor
IGHM 5247: *Case Studies in COVID-19* (This course is taught completely on-line through taped/posted lectures with live course thread), Vanderbilt University School of Medicine

Teaching Activities

PhD Committee Membership

- 2011-2012 Zhuo Song, Vanderbilt University Medical Center, Vanderbilt Core for Human Genetics Research (CHGR)/Human Genetics,
Mitochondrial Toxicity Research
- 2016- Aggrey Mweemba, MD; Nephrologist; University Teaching Hospital, Lusaka, Zambia,
Tenofovir-associated kidney toxicity research among HIV-infected and exposed young adults/adolescents
- 2017-2019 Lloyd Mulenga, MD; Internal Medicine/Infectious Diseases; University Teaching Hospital, Lusaka, Zambia

Insulin Resistance and Viral Load Suppression among HIV-Positive Adults

2017- Freeman Chabala, MS, BSc; Biochemistry Lecturer, Biomedical Scientist; University of Zambia, University Teaching Hospital; Lusaka, Zambia
Risk Predictive Tool for Acute Kidney Injury among At-Risk HIV-Positive Adults

Infectious Disease Fellowship Trainees Scientific Oversight Committee Membership

2011-2015 Yuri van der Heijden, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Tuberculosis/Drug Resistance Research.*

2011-2015 Heather N. Paulin, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Global Health/Predictors of HIV Voluntary Counseling and Testing Among Females in Rural Mozambique* (Primary Research Mentor).

2012-2013 Moises Huaman, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Tuberculosis/Global Health Research.*

2012-2015 Jessica Castilho, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Cancer Epidemiology/Global Health Research.*

2014-2015 Nathan Bullington, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Global Health / Utilization of Mobile Clinics as a Bridging Strategy for the Provision of Combination Antiretroviral Therapy/Comprehensive HIV Services in rural Mozambique.*

2014-2015 Mary Hopkins, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *HIV clinical outcomes/Global Health.*

2017- James G. Carlucci, MD, MPH; Vanderbilt University Medical Center, Division of Pediatric Infectious Diseases. *HIV Implementation Science with focus on Pediatric HIV engagement and retention in care.*

2016-2018 Folasade Arinze, MD, MPH; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Global Health / Immunodeficiency at Antiretroviral Therapy Start: Five Year Adult Data (2012-2017) Based on Evolving National Policies in Rural Mozambique.*

2017-2018 David Dobrzynski, MD; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases. *Antibiotic Stewardship/Hospital Epidemiology.*

Mentored Pre- and Post-Doctoral Trainees

Pre-Doctoral trainees

2005-2014	Sikhulile Moyo, BSc, MPH; (Research Mentor); Associate Laboratory Director, Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP), Gaborone, Botswana. <i>HIV complications (including point of care diagnostics to detect lactic acidosis among ART-treated adults)</i> . Now completing PhD; Stellenbosch University, Cape Town, South Africa); while still working as a Laboratory Scientist, Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education (BHP), Gaborone, Botswana.
2006-2008	Devan L. Darby Bartels MD, MPH; Princeton AIDS in Africa Fellow in Botswana (Primary On-Site Research Mentor/Advisor). <i>HIV and adherence to ART</i> . Now working as a Pediatric Anesthesiologist, Massachusetts General Hospital, Boston, MA.
2007-2008	Amy Wu, Harvard Undergraduate Student in Botswana (Primary On-Site Research Co-Mentor/Advisor). <i>HIV genotypic drug resistance</i> . Now working as CFO, Global Digital, New York, New York.
2008-2013	Sarah M. Ashburn, MD; Harvard Undergraduate Student in Botswana (Primary On-Site Research Mentor/Advisor); Johns Hopkins University Center for Global Health MSPH Program. <i>HIV outcomes</i> . Now working for Clinton HIV/AIDS Foundation, Boston, MA.
2008-2012	Lindsey L. Stephens, MD; Princeton AIDS in Africa Fellow in Botswana (Primary On-Site Research Mentor/Advisor). <i>Adolescent HIV / HIV Prevention</i> . Now working as an Internist; University of California San Francisco, San Francisco, CA.
2008-2011	Allison N. Martin, MD, MPH; Vanderbilt University School of Medicine Emphasis Program in Liberia and US at Vanderbilt (Primary Research Mentor and Faculty Advisor). <i>HIV Prevention</i> . Now at University of Virginia Medical Center, completing her Internal Medicine Residency training; Charlottesville, VA.
2011-2014	Jordan J. Cohen, MD; Vanderbilt University School of Medicine, Nashville TN; Emphasis (Student Research) Program (Primary Research Mentor and Faculty Advisor); <i>Adolescent HIV/ HIV Prevention (Kenya and South Africa)</i> . Now completing his Emergency Medicine residency training; Brown University Medical Center, Providence, RI.
2013-2015	M. Katherine Charles, MD, MPH; Vanderbilt University School of Medicine, Nashville, TN; Medical Student research project (Primary Research Mentor and Faculty Advisor). <i>HIV / Tuberculosis co-infection (TB screening, prevention, and diagnosis)</i> . Now completing her Internal Medicine residency training; Duke University Medical Center, Durham, NC.
2013-2015	Mary DeAgostino, MD, MPH; (Primary Research Mentor and Faculty Advisor for her MPH thesis), Vanderbilt University School of Medicine. <i>Women's and Adolescent Health</i>

/ Global Health (East Africa/Kenya). Now completing her Obstetrics and Gynecology residency training at the University of Pennsylvania, Philadelphia, PA.

2014-2016 Cristin Quinn Fritz, MD; (Primary Research Mentor and Faculty Advisor for her MPH thesis); Vanderbilt University School of Medicine. *HIV Care and Treatment / Site-level data*. Now completing her Pediatrics residency at Vanderbilt University Medical Center.

2019- Bentley Okoko, MD; (Research Mentor for his MPH thesis); Vanderbilt University Medical Center. Health Equity / healthcare disparities (work focused in sub-Saharan Africa and specifically Cameroon, where he is originally from).

2019- Victoria Umotoni, MD; (Research Mentor for his MPH thesis); Vanderbilt University Medical Center. Reproductive health / Mental health / Infectious Diseases (work focused in sub-Saharan Africa and specifically Rwanda, where she is originally from).

Post-Doctoral trainees

2002-2005 Ava Avalos, MD; (Primary On-Site Research Mentor/Advisor for her research experience in Gaborone, Botswana). *HIV/AIDS Treatment and Management of Opportunistic Infections*. Now works for Botswana Ministry of Health, Gaborone, Botswana.

2004-2005 Christopher G. Turner, MD, MPH; (Primary On-Site Research Mentor/Advisor for his research experience in Gaborone and Maun, Botswana). *HIV Inpatient Medical Ward Outcomes*. Now works as Pediatric Surgery attending engaged in research at University of Michigan (Ann Arbor, MI).

2004-2005 Gobuiwang Khilly Kurusa (Gasenna), MD; Fogarty Scholar in Botswana (Primary On-Site Research Mentor/Advisor). *HIV outcomes / engagement in care*. Now works as Infectious Disease physician, Gaborone, Botswana.

2004-2011 Natalie T. Do, PharmD; Fulbright Scholar in Botswana & the US (Primary On-Site Research Mentor/Advisor). *Predictors of Adherence among HIV-positive ART-treated adults in Botswana*. D.O. Degree obtained at Western University Health Sciences, California. Now works as Psychiatrist, San Diego, CA.

2005-2006 Linda K. Shipton, MD; Brigham and Women's Hospital Infectious Diseases Fellow (One Year ID Fellowship Research Experience/Elective at Princess Marina Hospital, Gaborone, Botswana) (On-Site Research Co-Mentor). *HIV / Tuberculosis co-infection* Now works as Assistant Professor of Medicine, Harvard Medical School, Boston, MA.

2005-2008 Melissa A. Briggs-Hagen, MD, MPH; Princeton AIDS in Africa Fellow in Botswana (Primary Research Mentor/Advisor). *Role of Traditional healers in HIV care* Head / Care & Treatment Branch, Centers for Disease Control & Prevention (CDC) Mozambique, Maputo, Mozambique (just recently moved to Pretoria, South Africa to take a more senior CDC position).

2008-2010 John R. Koethe, MD, MSCI; International Fogarty Training Scholarship in Zambia and United States at Vanderbilt (Primary Research Mentor and Faculty Advisor). *HIV Nutrition and Metabolic Complications (including Obesity/inflammation)*.

Now works as Assistant Professor, Vanderbilt University Medical Center, Department of Medicine, Division of Infectious Diseases.

- 2010-2013 Deidra D. Parrish, MD, MPH; International Fogarty Training Scholarship in Nigeria & the US at Vanderbilt (Primary Research Mentor and Faculty Advisor). *HIV outcomes and complications in Nigeria (including causes of morbidity and mortality among ART-treated adults)*. Now has leadership position at Metro Health, Tuberculosis Branch, Nashville, TN.
- 2011-2014 Heather N. Paulin, MD, MPH; Vanderbilt University Medical Center, Division of Infectious Diseases; (Primary Research Mentor and Faculty Advisor). *Global health / HIV testing service awareness and service uptake among female heads of household in rural Mozambique: results from a province-wide survey*. She completed her Epidemiologic Intelligence Service (EIS) fellowship, Centers for Disease Control and Prevention (CDC); Now working in the Global AIDS Program (GAP), HIV Prevention; CDC Atlanta, GA.
- 2011-2013 Bethan McDonald, PhD; Post-Doc at King's College in London (Co-Research Mentor and Faculty Advisor with her ongoing *HIV/AIDS Inflammation and Mortality Research* with the Botswana-Harvard School of Public Health AIDS Initiative Partnership for HIV Research and Education in Gaborone, Botswana). Now faculty member in the Division of Infectious Diseases, Kings College, London, United Kingdom.
- 2012-2013 Crispin Moyo, MD; Ministry of Health (Zambia); Lusaka, Zambia. Member of his mentoring committee and Co-Investigator in his clinical research study evaluating antiretroviral medication-related laboratory adverse events. *HIV treatment outcomes*. Now working for Zambia Ministry of Health, Lusaka, Zambia.
- 2013-2015 Nathan Bullington, MD; Vanderbilt University Medical Center; Division of Infectious Diseases; (Primary Research Mentor and Faculty Advisor). *Global Health / Utilization of Mobile Clinics as a Bridging Strategy for the Provision of Combination Antiretroviral Therapy/Comprehensive HIV Services in rural Mozambique*. Now working in Private Infectious Diseases practice, Louisville, KY.
- 2013-2016 Monica Negrete, MD, MPH; Friends in Global Health/Vanderbilt University (Mozambique—PEPFAR grant Technical Director); active PI of the grant which she began work on in March 2013 (actively engaged in mentoring her ongoing clinical research activities). *Vulnerable populations (refugee resettlement)*. Now working as a public health researcher (also obtaining her PhD) with faculty position at University of Colombia, Bogota, Colombia.
- 2016-2018 Christopher C. Wahlfeld, PhD, MPH; (Co-Primary Research Mentor for his MPH thesis); *HIV Rapid Diagnostic Test Inventories in Zambézia Province, Mozambique: A Tale of Two Test Kits*. Now working for not for profit organization in Nashville, TN.
- 2016-2018 Meghan Rieth, MD; Vanderbilt University Research Assistant II (Active PI of the grant she worked on, and I served as her Supervisor/Primary Research Mentor). *HIV Prevention (including PMTCT) in rural Mozambique*. Now has an academic position within the Department of Pediatrics (Research fellow/Pediatrician), University of Colorado School of Medicine, Denver CO.

- 2012- Lloyd B. Mulenga, MD; Centre for Infectious Disease Research in Zambia (CIDRZ); Primary Research Mentor for his 5-week Vanderbilt-sponsored (VIRDE) grant-writing training but still with ongoing mentoring/collaboration. *HIV outcomes (including HIV and diabetes mellitus as well as kidney complications)*. Now works as the Clinical Head of the Adult Infectious Disease Centre at University Teaching Hospital in Lusaka, Zambia.
- 2012- Aggrey Mweemba, MD; University Teaching Hospital. Lusaka, Zambia. Primary Research Mentor for his 5-week Vanderbilt-sponsored (VIRDE) grant-writing training but still with ongoing mentoring including serving on his PhD thesis committee). Now works as the Head of the Renal Unit in the Department of Medicine in Lusaka, Zambia.
- 2013-2019 Carolyn M. Audet, PhD; Vanderbilt University Medical Center; Department of Health Policy, Vanderbilt Institute for Global Health (Research Advisor/Mentor). *HIV engagement/retention in care (Male engagement strategy / couples-based ART and PMTCT in rural Mozambique)*. Now working as Assistant Professor, Vanderbilt University Medical Center, Department of Health Policy, Vanderbilt Institute for Global Health.
- 2013-2018 Joshua R. Viele, RN; Vanderbilt University Medical Center, Vanderbilt Institute for Global Health. Research Advisor/Supervisor---I am the PI of the grant he is working on; actively engaged in mentoring his ongoing clinical research activities. *HIV Quality Improvement*. Now working as Quality Improvement Analyst, Vanderbilt Institute for Global Health.
- 2015- Catrina Mugglin, MD; Research Mentor (for her PhD thesis work focusing on chronic diseases/NCDs). *Non-communicable diseases (NCDs) and HIV*. Now working at the University of Bern, Institute of Social and Preventive Medicine (ISPM), Bern, Switzerland (faculty / research appointment).
- 2016-2018 Folasade ("Sade") Arinze, MD, MPH; Vanderbilt University Medical Center, Vanderbilt Division of Infectious Diseases (Primary Research Mentor). *Global Health / HIV Care and Treatment*. Now has academic role at WellStar Atlanta Medical Center, WellStar Kennestone Hospital, Atlanta, GA.
- 2017-2020 James G. Carlucci, MD, MPH; Vanderbilt University School of Medicine; Division of Pediatric Infectious Diseases; (Research Mentor and Faculty Advisor); *Implementation Science research (focus on maternal child health, identifying ways to improve continuum of care outcomes among HIV-exposed and HIV-infected infants in resource-constrained settings)*. Now working as Assistant Professor, Ryan White Center for Pediatric Infectious Diseases & Global Health at Indiana University School of Medicine.
- 2018- Jose A. Tique, MD, MPH; Vanderbilt University Medical Center / Friends in Global Health Technical Director-- I am the PI of the grant which he is working on; actively engaged in mentoring his ongoing technical work/implementation science research initiatives. *HIV Quality Improvement / Program Evaluation*. Now working as Technical Director for Friends in Global Health (FGH), based in Maputo, Mozambique.
- 2019- June Fabian, MD, MMed; University of the Witwatersrand University, Department of Internal Medicine, Donald Gordon Medical Center, Johannesburg, South Africa. She is a nephrologist engaged in HIV outcomes/translational work (including personalized medicine) and I serve as one of her primary research mentors.

- 2019- Aminu Abba Yusuf, MD; Bayero University, Aminu Kano Teaching Hospital (AKTH), Kano, Nigeria. He has Fogarty / NIH funding to evaluate cytopenia (given his Hematology background) among ART-treated adults in West Africa, and I am his Primary Research Mentor.
- 2018- Aimalohi (“Aima”) Ahonkhai, MD, MPH; Vanderbilt University School of Medicine; Division of Infectious Diseases; (Research Mentor); HIV/AIDS, *Implementation Science research (focus on adolescents/young adults and specifically engagement and retention in care including utilization of mHealth solutions), Mental health/distress*. Now working as Assistant Professor, Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center (VUMC).
- 2018- Usman J. Wudil, MBBS, MPH; Vanderbilt Institute for Global Health (VIGH); (Research Mentor); HIV/AIDS, Implementation Science with focus on HIV-associated kidney complications and disease (including genetic risk). Now working as Clinical & Translational Research Coordinator for the Vanderbilt Institute for Global Health (VIGH).

Research Grant Support

Currently active research grants (as of 3/15/2021):

1NU2GGH001943 (PI: Wester) 9/30/2016 - 9/29/2021
CDC (PEPFAR) \$34,758,413.00

Avante: Towards Epidemic Control

The purpose of the Avante program is to control the HIV epidemic by supporting the sustainable implementation of Ministry of Health (MOH) HIV and TB services in Zambézia province. Avante will provide technical assistance (TA) to the Government of the Republic of Mozambique (GRM) at the national, provincial, district and health facility level for activities that have a significant impact to control the epidemic, leveraging community structures that can catalyze program implementation. Key programmatic areas include: i) prevention; ii) adult care, support, and treatment; iii) HIV/TB; and iv) pediatric care, support, and treatment.

1U01DK112271 (MPI/Contact PI: Wester) 9/15/2017 – 8/31/2022
NIH/NIDDK \$525,054

Optimal Management of HIV Infected Adults at Risk for Kidney Disease in Nigeria

In this clinical trial, we plan to determine the optimal means to prevent or slow the progression of kidney disease among genetically at-risk northern Nigerian HIV-infected adults. Based on data from studies of diabetic kidney disease that used medications that block the renin angiotensin aldosterone system (RAAS), we plan to evaluate whether RAAS inhibition in HIV-positive adults produces similarly promising results. We will screen 2,600 HIV-positive ART-experienced adults to: 1) determine the prevalence of *APOL1* risk variants and assess whether *APOL1* HR status correlates with prevalent albuminuria, estimated glomerular filtration rate, and/or prevalent CKD; 2) assess, via a randomized, placebo-controlled trial (RCT) in a subset of these participants with microalbuminuria (n=280) whether addition of the ACEi lisinopril, compared to standard of care, significantly reduces the incidence or progression of albuminuria; and 3) determine whether the *APOL1* HR genotype is associated with worse kidney outcomes (i.e. eGFR slope or regression of albuminuria) among participants in the RCT. This study will provide the first RCT evidence informing the optimal strategy to slow CKD progression in HIV-positive adults.

1D43TW011544 (MPI: Aliyu M, Wester CW, and Sani M) 4/22/2020 - 12/31/2024
NIH/Fogarty International Center (FIC) \$280,900

Vanderbilt-Nigeria Building Research Capacity in HIV and Non-Communicable Diseases (V-BRCH)

The program will accept eight junior faculty fellows from AKTH, provide competitive seed grants to 10 mentor-mentee teams, and fund 10 physicians to receive Master of Public Health degrees from Bayero University Kano or Master of Science in Clinical Investigation degrees from Vanderbilt, in addition to providing training for AKTH research support staff. Program participants will have the opportunity to develop expertise in clinical trials methodology, grant writing and HIV-associated non-communicable diseases epidemiology.

Other program components include:

- Continuous mentoring through paired mentoring arrangements, virtual meetings, and career development seminars
- Opportunities to participate in the Vanderbilt Institute for Research Development and Ethics (“VIRDE”) program at VUMC, transitioning to an AKTH-based program in later years
- On-site workshops in Nigeria
- Leveraging training activities conducted by other FIC-funded training programs in Nigeria and sub-Saharan Africa (South-South collaborative opportunities)

VUMC65172 (720-656-18-C-00 (PI of sub-contract to VUMC: Wester))

12/5/2017 - 7/30/2022

U.S. Agency of International Development (USAID)

\$290,065

Chemonics International, Inc.

Integrated Malaria Program (IMaP) in Mozambique

The goal of this 5-year grant (IMaP) is to contribute to reducing malaria-associated mortality, morbidity, and parasitemia in four high malaria burden provinces (Zambézia, Nampula, Cabo Delgado, and Tete). IMaP will achieve this goal through three objectives:

- 1) Support the implementation of proven malaria interventions at community and facility levels, in alignment with the national Malaria Strategic Plan (NMSP).
- 2) Strengthen management capacity of the provincial and district Ministry of Health (Ministério de Saúde, MISAU) personnel to provide oversight and supervision of malaria interventions, and
- 3) Improve health management information system (HMIS) data reporting, analysis, and use at the provincial and district levels.

Grants completed (as of 3/15/2021):

2012-2017 ***Avante Zambézia: Technical Assistance to the Ministry of Health (MOH) for HIV Services and Program Transition in Zambézia***; U2GGH002071 (formerly GGH00812) (PI: Wester) CDC/GAP (PEPFAR)

This large CDC-PEPFAR-funded initiative entitled “*Avante Zambézia*” (“*Go forward*” Zambézia province) allowed Dr. Wester and his team to provide comprehensive HIV services (including the provision of ART including ART for PMTCT) to HIV-infected persons residing in 14 of Zambézia provinces 23 districts. *Avante Zambézia* goals were as follows: (i) To expand HIV-related clinical services; (ii) To enhance clinical knowledge and skills among health care workers at health facility, district, and provincial levels to provide quality HIV-related care; (iii) To increase the quality and capacity of health care planning and management among health sector staff at facility, district, and provincial levels; (iv) To strengthen linkages between communities and the health sector in order to increase enrollment and retention of HIV+ patients; and (v) To strengthen capacity of existing local organizations and prepare for transition.

2011-2016 International Epidemiologic Databases to Evaluate AIDS (IeDEA); ***IeDEA Network Coordinating Center (INCC) at Vanderbilt***; 1U01AI096186-05 (Wester/Lindegren, Co-PIs); 7/1/2011-6/30/2016. NIAID/NIH

As Co-PI, Dr. Wester worked with Dr. Lindegren to assist in the overall management, coordination, administration, and direction of the project, including participation in all requisite IeDEA network activities, and assisted in the oversight of the following: coordination and administration of meetings, including investigator and specialty conference calls, as well as transforming the IeDEA website into an online Community of Practice, with both password-protected internal sections for investigators and NIH staff (as well as open external sections for public access), to advance the IeDEA scientific agenda and foster multi-regional research projects within the IeDEA consortium.

2013-2016 ***HIV Quality Improvement Research, Zambezia Province, Mozambique.*** (Wester: PI of sub- contract); 6/1/2013 – 5/31/2016; HealthQUAL International, New York State Dept. of Health AIDS Institute Quality of Care Program, Vanderbilt University/Friends in Global Health (FGH); Federal ID# 62-0476822

The goal of this grant was to build the in-province capacity of technical staff to conduct quality improvement work to improve the HIV care being provided to adults and children.

2014-2015 ***International Epidemiologic Databases to Evaluate AIDS (IeDEA)***; North America 5U01 A1069918-08; ***North American AIDS Cohorts Collaboration on Research and Design (NA ACCORD)***; ***8 U01 AI68818 Supplement***; 7/01/2014 – 6/30/2015; (Wester: PI)

In this supplement to the North American AIDS Cohorts Collaboration on Research & Design (NA ACCORD) project of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) consortium, we conducted analyses that address two research areas of emerging importance as HIV-infected patients survive longer and HIV becomes more of a chronic disease, namely, (i) the role of angiotensin converting enzyme-inhibitors (ACE-I) and angiotensin receptor blockers (ARBs), both potent anti-inflammatory agents, in the prevention of mortality and the development of cardiovascular, metabolic, and other inflammation-related non-AIDS defining events (NADEs); and (ii) the effect of being overweight or obese (a growing proportion of HIV-infected adults) on CD4+T-cell recovery on antiretroviral therapy (ART).

2007-2012 NIAID/NIH K23AI073141 (Wester, PI); Vanderbilt University; ***Risk Factors for Lactic Acidosis and Pancreatitis among HAART-Treated Adults in Botswana.***

In-depth study evaluating the clinical, laboratory, and host genetic factors associated with higher than expected rates of mitochondrial toxicity (specifically, lactic acidosis and pancreatitis) among combination antiretroviral therapy (ART)-treated adults in the region. This project uses data and specimens already prospectively collected during a clinical trial in Botswana. Career development activities include additional experience in: (a) the design and implementation of global multi-center clinical trials, (b) development of research infrastructure in Africa, and (c) developing additional, fundable translational research projects aimed at preventing or treating antiretroviral therapy-related complications in both resource-limited and –replete settings.

2009-2013 NIAID/NIH P30AI 060354 (Wester, PI) Center for AIDS Research (CFAR) Harvard University; ***Risk Factors for the Development of Nevirapine-Associated Toxicity in Southern Africa.***

The major goals of this project were to continue my involvement in ARV-associated toxicity and host genetics and comprehensively evaluate the risk factors for nevirapine-associated hypersensitivity (skin) reactions which preliminarily are higher than rates reported elsewhere. Specimens already prospectively collected during a recently completed clinical trial in Botswana.

2012-2015 ***Optimizing Integrated PMTCT Services in Rural North-Central Nigeria.***
1R01HD075075-02 (PI: Aliyu); 9/28/2012 – 6/30/2014; NIH / NICHD;

The purpose of this R01 proposal was to evaluate the impact and cost-effectiveness of a family-focused integrated prevention of mother-to-child transmission of HIV (PMTCT) package comprising task shifting of PMTCT services (including antiretroviral therapy) to lower-cadre workers, adoption of point-of-care CD4 testing, and a prominent role for influential family members of HIV-infected mothers in rural Nigeria. Role: Co- Investigator

2012-2014 Vanderbilt-Meharry Center for AIDS Research (CFAR); P30AI 060354
(Wester and Koethe, Co-PI's); 07/01/2012 – 08/31/2014; NIAID/NIH. ***Pilot Study of Extended-Release Exenatide to Improve Glucose Control and Reduce Systemic Inflammation in Diabetic, HIV-Infected Adults on Antiretroviral Therapy.***

Results informed understanding of the benefit of an FDA-approved agent to improve glucose intolerance and reduce markers of inflammation demonstrated to predict adverse cardiovascular events among HIV-positive adults on ART.

Publications

A full list of my publications may be found at:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/1HSsewwv6gd5A/bibliography/43390763/public/?sort=date&direction=ascending>.

Peer-Reviewed Articles

1. **Wester CW**, Ariga D, Nathan C, Rice TW, Pulvirenti J, Patel R, Kocka F, Ortiz J, Weinstein RA. Possible overestimation of penicillin resistant *Streptococcus pneumoniae* colonization rates due to misidentification of oropharyngeal streptococci. *Diagn Microbiol Infect Dis*. 2002; 42:263-8. PMID: 12007444.
2. **Wester CW**, Durairaj L, Evans AE, Schwartz DS, Husain S, Martinez E. Antibiotic resistance: a survey of physician perceptions. *Arch Intern Med*. 2002; 162:2210-16. PMID: 12390064.
3. Bussmann H, Novitsky V, **Wester CW**, Peter T, Masupu K, Gabaitiri L, Kim S, Gaseitsiwe S, Ndung'u T, Marlink R, Thior I, Essex M. HIV-1 subtype C drug-resistance background among ARV-naïve adults in Botswana. *Antiviral Chem Chemother*. 2005; 16:103-15. PMID: 15889533.
4. Bussmann H, **Wester CW**, Masupu KV, Peter T, Gaolekwe SM, Kim S, Reich AM, Ahn S, Wu Y, Thior I, Essex M, Marlink R. Low CD4+ T-lymphocyte values in human immunodeficiency virus-negative adults in Botswana. *Clin Diagn Lab Immunol*. 2004; 11:930-5. PMID: 15358655.
5. **Wester CW**, Bussmann H, Avalos A, Ndwapi N, Gaolathe T, Cardiello P, Bussmann C, Moffat H, Mazonde P, Marlink R. Establishment of a public adult antiretroviral treatment clinic in urban Botswana: lessons learned. *Clin Infect Dis*. 2005; 40:1041-1044. PMID: 15824998.
6. **Wester CW**, Kim S, Bussmann H, Avalos A, Ndwapi N, Peter TF, Gaolathe T, Mujugira A, Busang L, Vanderwarker C, Cardiello P, Johnson O, Thior I, Mazonde P, Moffatt H, Essex M, Marlink R. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. *J Acquir Immune Defic Syndr* 2005; 40(3):336-343. PMID: 16249709.
7. Bussmann H, **Wester CW**, Ndwapi N, Vanderwarker C, Gaolathe T, Tirelo G, Avalos A, Moffat H, Marlink R. Hybrid data capture for monitoring patients on highly active antiretroviral therapy (HAART) in urban Botswana. *Bull World Health Organ* 2006, 84(2):127-131. PMID: 16501730.
8. Doualla-Bell F, Gaseitsiwe S, Ndung'u T, Modukanele M, Peter T, Novitsky V, Ndwapi N, Gaolathe T, Avalos A, **Wester CW**, Bussmann H, Cardiello P, Marlink R, Moffatt H, Thior I, Wainberg MA, Essex M. Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. *Antivir Chem Chemother*. 2004; 15(4):189-200. PMID: 15457680.
9. **Wester CW**, Bussmann H, Moyo S, Avalos A, Gaolathe T, Ndwapi N, MacGregor RR and Marlink RG. Serological Evidence for HIV-Associated Infections among HIV-1C Infected Adults in Botswana. *Clin Infect Dis* 2006, Dec 15; 43(12):1612-1615. PMID: 17109297.
10. Do N, Phiri K, Bussmann H, Foya K, Marlink RG, **Wester CW**. Psychosocial Factors Affecting Medication Adherence among HIV-1 Infected Adults Receiving Combination Antiretroviral Therapy (cART) in Botswana. *AIDS Research and Human Retroviruses* 2010; 26(6): 685-691. PMID: 20518649.
11. **Wester CW**, Okezie O, Thomas AM, et al. Higher-Than-Expected Rates of Lactic Acidosis among Highly Active Antiretroviral Therapy-Treated women in Botswana: Preliminary Results from a Large Randomized Clinical Trial. *J Acquir Immune Defic Syndr* 2007, November; 46 (3): 318-322. PMID: 18090299.
12. Bussmann H, **Wester CW**, Wester CN, et al. Pregnancy Rates and Birth Outcomes among Women on Efavirenz-Containing Highly Active Antiretroviral Therapy in Botswana. *J Acquir Immune Defic Syndr* 2007, July 1; 45 (3): 269-273. PMID: 17450102.
13. Novitsky V, **Wester CW**, DeGruttola V, et al. The Reverse Transcriptase 67N 70R 215Y Genotype is the Predominant TAM Pathway Associated with Virologic Failure among HIV type 1C-Infected Adults Treated with ZDV/ddI-containing HAART in Southern Africa. *AIDS Res Hum Retroviruses* 2007, Jul; 23(7): 868-878. PMID: 17678469.

14. Shipton LK, **Wester CW**, Stock S, et al. Safety and Efficacy of Nevirapine- and Efavirenz-Based Antiretroviral Treatment in Adults Treated for TB-HIV Co-Infection in Botswana. *Int J Tuberc Lung Dis* 2009, Mar; 13(3):360-366. PMID: 19275797.
15. Bussmann C, Rotz P, Ndwapi N, Baxter D, Bussmann H, **Wester CW**, et al. Strengthening Healthcare Capacity through a Responsive, Country-Specific, Training Standard: The KITSO AIDS Training Program's Support of Botswana's National Antiretroviral Therapy Rollout. *Open AIDS J* 2008; 2:10-16. PMID: 18923699.
16. Bussmann H, **Wester CW**, Ndwapi N, et al. Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program. *AIDS* 2008, Nov 12; 22(17): 2303-2311. PMID: 18981769.
17. Bussmann H, **Wester CW**, Thomas AM, et al. Response to Zidovudine/Didanosine-Containing Combination Antiretroviral Therapy among HIV-1 Subtype C Infected Adults in Botswana: Two-Year Outcomes from a Randomized Clinical Trial. *J Acquir Immune Defic Syndr* 2009, May 1; 51(1):37-46. PMID: 19282782.
18. Mujugira A, **Wester CW**, Kim SA, Bussmann H, and Gaolathe T. Patients with Advanced HIV Type 1 Infection Initiating Antiretroviral Therapy in Botswana: Treatment Response and Mortality. *AIDS Res Hum Retroviruses* 2009, Feb; 25(2): 127-133. PMID: 19239353.
19. **Wester CW**, Bussmann H, Koethe JR, Moffat C, Vermund SH, Essex M, Marlink RG. Adult Combination Antiretroviral Therapy in sub-Saharan Africa: Lessons from Botswana and Future Challenges. *HIV Ther* 2009, Sep 1; 3(5):501-526. PMID: 20161344.
20. **Wester CW**, Thomas AM, Bussmann H, et al. Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana. *AIDS* 2010; 24 (Suppl 1): S27-S36. PMID: 20023437.
21. Novitsky V, Wang R, Bussmann H, Lockman S, Baum M, Shapiro R, Thior I, Wester C, **Wester CW**, et al. HIV-1 Subtype C-Infected Individuals Maintaining High Viral Load as Potential Targets for the "Test-and-Treat" Approach to Reduce HIV Transmission. *PLOS ONE* 2010, Apr 12; 5(4): e10148. PMID: 20405044.
22. Koethe JR, Limbada MI, Giganti MJ, Nyirenda CK, Mulenga L, Wester CW, Chi BH, Stringer JS. Early immunologic response and subsequent survival among malnourished adults receiving antiretroviral therapy in Urban Zambia. *AIDS* 2010, Aug 24; 24(13): 2117-2121. PMID: 20543657.
23. Bussmann H, de la Gomez F, Roels T, Bodika SM, Moyo S, Taffa N, **Wester CW**, Anderson M, Mine M, Bile EC, Yang C, Mphoyakgosi K, Mlotshwa B, Tsiane M, Seipone K, Makhema MJ, Novitsky V, Essex M. Prevalence of Transmitted HIV Drug Resistance in Botswana: Lessons Learned from the HIVDR-Threshold Survey Conducted among Women Presenting for Routine Antenatal Care as part of the 2007 National Sentinel Survey. *AIDS Res Hum Retroviruses* 2011, Apr; 27(4): 365-72 [Epub 2010 Oct 29]. PMID: 21034246.
24. **Wester CW**, Koethe JR, Shepherd BE, Rebeiro PF, Kipp AM, Hong H, Bussmann H, Stinnette SE, McGowan CC, Sterling TR, and Marlink RG. Non-AIDS-Defining Events among HIV-1-Infected Adults Receiving Combination Antiretroviral Therapy in Resource-Replete versus Resource-Limited Urban Setting. *AIDS* 2011, Jul 31; 25(12):1471-1479. PMID: 21572309.
25. Stitelman OM, **Wester CW**, DeGruttola V, van der Laan MJ. Targeted Maximum Likelihood Estimation of Effect of Modification Parameters in Survival Analysis. *Int J Biostat* 2011; 7(1): Article 19. PMID: 21556287.
26. Koethe JR, Blevins M, Nyirenda C, Kabagambe EK, Shepherd BE, **Wester CW**, Zulu I, Chiasera JM, Mulenga LB, Mwangi A, Heimbürger DC. Nutrition and inflammation serum biomarkers are associated with 12-week mortality among malnourished adults initiating antiretroviral therapy in Zambia. *J Int AIDS Soc* 2011; 14:19. PMID: 21477359.
27. **Wester CW**, Stitelman OM, DeGruttola V, Bussmann H, Marlink RG, van der Laan MJ. Effect Modification by Sex and Baseline CD4+ Cell Count among Adults Receiving Combination Antiretroviral Therapy in Botswana: Results from a Clinical Trial. *AIDS Res Hum Retroviruses*; Volume 28, No. 9, 2012:981-988 [Epub 2012 March 23]. PMID: 22309114.
28. **Wester CW**, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson S, Winkler CA, O'Brien SJ, Essex M, D' Aquila RT M D, DeGruttola V, Marlink RG. Risk factors for Symptomatic Hyperlactatemia and Lactic Acidosis Combination Antiretroviral Therapy-Treated Adults in Botswana: Results from a Clinical Trial. *AIDS Res Hum Retroviruses* 2012, Apr 28. [Epub ahead of print; PMID: 22540188.
29. Moyo S, Bussmann H, Mangwendeza P, Dusara P, Gaolathe T, Mine M, Musonda R, van Widenfelt E, Novitsky V, Makhema J, Marlink RG, Essex M, **Wester CW**. Validation of a portable point-of-care lactate device for screening at-risk adults receiving combination antiretroviral therapy in Botswana. *J Antivir Antiretrovir* 2011; 3:4. PMID: 23087782.

30. Stephens LL, Bachhuber MA, Gungqisa N, Seloilwe E, Ntsiane M, Marlink RG, **Wester CW**. Survey on HIV/AIDS Knowledge, Attitudes, and Practices among Students at the University of Botswana. *Journal of AIDS and HIV Research* 2012 Jun 1;4(6):159-164; PMID: 3530163. PMID: 23275859.
31. Spinner MA, Paulin HN, and **Wester CW**. Duodenal Histoplasmosis Presenting with Upper Gastrointestinal Bleeding in an AIDS Patient. *Case Reports in Gastrointestinal Medicine*. Vol. 2012, Article ID 515872, 4 pages, 2012. doi:10.1155/2012/515872. PMID: 23091745.
32. McDonald B, Moyo S, Gabaitiri L, Gaseitsiwe S, Bussmann H, Koethe JR, Musonda R, Makhema J, Novitsky V, Marlink RG, **Wester CW**, Essex M. Persistently Elevated Serum Interleukin-6 Predicts Mortality Among Adults Receiving Combination Antiretroviral Therapy in Botswana: Results from a Clinical Trial. *AIDS Res Human Retroviruses*. 2013 Apr 16 [Epub ahead of print]; PMID: 23590237.
33. Sinxadi P, Dave JA, Samuels DC, Heckmann JM, Maartens G, Levitt N, **Wester CW**, Haas D, Hulgan T. Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected black South Africans: a pilot study. *AIDS Res Hum Retroviruses*. 2013 Feb 21. [Epub ahead of print]. PMID: 23428049.
34. Parrish DD, Blevins ML, Stinnette SE, Rebeiro PF, Shepherd BE, Sterling TR, McGowan CC, **Wester CW**. Virologic, Immunologic and Clinical Responses in Foreign-Born versus U.S.-Born HIV-Infected Adults Initiating Antiretroviral Therapy: An Observational Cohort Study. *PLOS ONE*. 2012; Volume 7(12): e52336. doi: 10.1371/journal.pone.0052336. PMID: 23284994.
35. Aliyu M, Blevins M, Parrish DD, Megazzini KM, Gebi UI, Muhammad MY, Vermund SH, and **Wester CW**. Risk Factors for Delayed Initiation of Combination Antiretroviral Therapy: Lessons Learned from An ART Program in Rural North Central Nigeria. *JAIDS*, 2013 May 30. [Epub ahead of print]; PMID: 23727981.
36. Koethe JR, Bian A, Shintani AK, **Wester CW**, Erdem H, and Hulgan T. An association between adiposity and serum levels of macrophage inflammatory protein-1 α and soluble CD14 in HIV-infected adults: results from a cross-sectional study. *Antivir Ther*. 2013 Jun 7. [Epub ahead of print]. PMID: 23748193.
37. Aliyu MH, Blevins M, Audet C, Shepherd BE, Hassan A, Onwujekwe O, Gebi UI, Kalish M, Lindegren ML, Vermund SH, and **Wester CW**. Optimizing PMTCT Service Delivery in Rural North-central Nigeria: Protocol and Design for a Cluster Randomized Study. *Contemp Clin Trials*. 2013 Sep;36(1):187-97. PMID: PMC3786261.
38. Cohen JJ, Blevins M, Mapenzi A, Reppart L, Reppart J, Mainthia R, and **Wester CW**. Overcoming the Perceived Barriers to Healthcare Access Among Single Mothers in Coastal Kenya. *Int J Public Health*. 2014 Feb;59(1):189-96. doi: 10.1007/s00038-013-0511-0. Epub 2013 Sep 21 PMID: 24057600.
39. Parrish DD, Blevins M, Megazzini KM, Shepherd BE, Mohammed MY, **Wester CW**, Vermund SH, and Aliyu MH. Haemoglobin recovery among HIV-1-infected patients on zidovudine-based antiretroviral therapy and other regimens in north-central Nigeria. *Int J STD AIDS*. 2013 Oct 8. PMID: 24104694.
40. Dunlap J, Foderington N, Bussell S, **Wester CW**, Audet CM, and Aliyu MA. Male involvement for the Prevention of Mother-to-Child Transmission: A Brief Review of Initiatives in East, West, and Central Africa. Invited review. *Current HIV/AIDS Reports (Global Epidemic Section)*; 2014 Jun;11(2):109-18. doi: 10.1007/s11904-014-0200-5. PMID: 24633806.
41. Aliyu MH, Blevins M, Megazzini KM, Dunlap J, Audet CM, Sodangi IS, Gebi UI, Shepherd BE, **Wester CW**, and Vermund SH. Correlates of suboptimal entry into early infant diagnosis in rural north-central Nigeria; *J Acquir Immune Defic Syndr*. 2014 Sep 1;67(1): e19-26. PMID: 24853310.
42. Moon TD, Jecquicene T, Blevins M, Lankford JR, **Wester CW**, Fuchs MC, Vermund SH. Mobile clinics for Increased access to antiretroviral therapy in rural Mozambique: Strategic use to capacitate fixed-site clinics. *Bull World Health Organ*, 2014 September; 92(9):680-684. Article ID: BLT.13.129478. Published online 19 June 2014.
43. Koethe JR, Jenkins CA, Turner M, Bebawy S, Shepherd BE, **Wester CW**, and Sterling TR. Body Mass Index and the Risk of Incident Non-Communicable Diseases after Starting Antiretroviral Therapy. *HIV Med*. Jan;16(1):67-72. doi: 10.1111/hiv.12178. Epub 2014 Sep 17. PMID: 25230709.
44. da Silva M, Blevins M, **Wester CW**, Manjolo J, Jose E, Gonzalez LC, Shepherd BE, Moon TD, Vaz LME. Patient Loss to Follow-Up Before Antiretroviral Therapy Initiation in Rural Mozambique. *AIDS Behav* (August 2014). Published online 06 August 2014; DOI 10.1007/s10461-014-0874-0; PMID: 25096897.

45. Duda SN, Farr AM, Lindegren ML, Blevins M, **Wester CW**, Wools-Kaloustian K, Ekouevi DK, Egger M, Hemingway-Foday J, Cooper DA, Moore RD, McGowan CC, and Nash D. Characteristics and Comprehensiveness of Adult HIV Care and Treatment Programs in Asia-Pacific, sub-Saharan Africa, and the Americas: Results of a Site Assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. *Journal of the International AIDS Society (JIAS)* 2014 Dec 15; 17:19045. doi: 10.7448/IAS.17.1.19045. PMID: 25516092
46. Aliyu MA, Blevins M, Parrish DD, Megazzini KM, Gebi UI, Muhammad MY, Ahmed ML, Das S, Nwanyanwu O, Shepherd BE, Vermund SH, and **Wester CW**. Risk Factors for Delayed Initiation of Combination Antiretroviral Therapy in Rural North-Central Nigeria. *J Acquir Immune Defic Syndr*. 2014 Feb 1;65(2): e41-9. PMID: 2372798
47. Moon TD, Ossemame EB, Green AF, Ndatimana E, José E, Buehler CP, **Wester CW**, Vermund SH, Olupona O. Antiretroviral therapy program expansion in Zambézia Province, Mozambique: Geospatial mapping of community-based and health facility data for integrated health planning. *PLOS One* 2014; 9(10): e109653. PMID: 25329169
48. Paulin HN, Vergara AE, Blevins M, Hinton N, Koethe JR, Vermund SH, Vaz LM, and **Wester CW**. HIV testing service awareness and service uptake among female heads of household in rural Mozambique: results from a province-wide survey. *BMC Public Health*. 2015 Feb 12; 15:132. PMID: 25881182.
49. Abraham AG, Althoff KN, Jing Y, Estrella MM, Kitahata MM, **Wester CW**, et al; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). End-stage renal disease among HIV-infected adults in North America. *Clin Infect Dis*. 2015 Mar 15;60(6):941-9. PMID: 25409471.
50. Audet CM, Chire YM, Vaz LM, Bechtel R, Carlson-Bremer D, **Wester CW**, Amico KR, Gonzalez-Calvo L. Barriers to Male Involvement in Antenatal Care in Rural Mozambique. *Qual Health Res* 2015 Apr 8. PMID: 25854615.
51. Aliyu MH, Blevins M, Arinze F, Megazzini KM, Bussell S, Dunlap J, Odoh C, Gebi UI, Muhammad MY, Shepherd BE, Audet CM, Vermund SH, and **Wester CW**. Enrolment trends in a comprehensive HIV programme in rural north-central Nigeria: improved care indices, but declining quality of clinical data over time. *Pathog Glob Health*. 2015 Mar;109(2):75-83. PMID: 25822098.
52. Aliyu MH, Blevins M, Parrish DD, Megazzini KM, Audet CM, Chan N, Odoh C, Gebi UI, Muhammad MY, Shepherd BE, **Wester CW**, Vermund SH. Pregnant women with HIV in rural Nigeria have higher rates of antiretroviral treatment initiation, but similar loss to follow-up as non-pregnant women and men. *Int Health*. 2015 Nov;7(6):405-11. doi: 10.1093/inthealth/ihv032. Epub 2015 May 25. PMID: 26012740.
53. Koethe JR, Jenkins CA, Lau B, Shepherd BE, Justice AC, Tate JP, Buchacz K, Napravnik S, Mayor AM, Horberg MA, Blashill AJ, Willig A, **Wester CW**, Silverberg MJ, Gill J, Thorne JE, Klein M, Eron JJ, Kitahata MM, Sterling TR, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and Canada. *AIDS Res Hum Retroviruses*. 2015 Sep 9. [Epub ahead of print]. PMID: 26352511.
54. Edwards LJ, Moisés A, Nzaramba M, Cassimo A, Silva L, Mauricio J, **Wester CW**, Vermund SH, Moon TD. Implementation of a health management mentoring program: year-1 evaluation of its impact on health system strengthening in Zambézia Province, Mozambique. *Int J Health Policy Manag*. 2015 Mar 12;4(6):353-61. PMID: 26029894.
55. Audet CM, Blevins M, Chire YM, Aliyu MH, Vaz LM, Antonio E, Alvim MFS, Bechtel R, **Wester CW**, Vermund SH. Engagement of Men in Antenatal Care Services: Increased HIV Testing and Treatment Uptake in a Community Participatory Action Program in Mozambique. *AIDS Behav*. 2016 Feb 23. [Epub ahead of print] PMID: 26906021.
56. Charles MK, Lindegren ML, **Wester CW**, Blevins M, Sterling TR, Dung NT, Dusingize JC, Avit-Edi D, Durier N, Castelnovo B, Nakigozi G, Cortes CP, Ballif M, Fenner L; International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration. Implementation of Tuberculosis Intensive Case Finding, Isoniazid Preventive Therapy, and Infection Control ("Three I's") and HIV-Tuberculosis Service Integration in Lower Income Countries. *PLOS ONE*. 2016 Apr 13;11(4): e0153243. PMID: 27073928.
57. Aliyu MH, Blevins M, Audet CM, Kalish M, Gebi UI, Onwujekwe O, Lindegren ML, Shepherd BE, **Wester CW**, and Vermund SH. Integrated prevention of mother-to-child HIV transmission services, antiretroviral therapy initiation, and maternal and infant retention in care in rural north-central Nigeria: a cluster-randomised controlled trial. *Lancet HIV*; 2016; Volume 3, No. 5; May;3(5): e202-11. PMID: 27126487.

58. Boehmer A, Audet CM, Blevins M, Gebi UI, **Wester CW**, Vermund SH, Aliyu MH. Patient and Provider Satisfaction with a Comprehensive Strategy to Improve Prevention of Mother-to-Child HIV Transmission Services in Rural Nigeria. *J Acquir Immune Defic Syndr*. 2016 Aug 1;72 Suppl 2: S117-23. PMID: 2735549.
59. Fritz CQ, Blevins M, Lindegren ML, Wools-Kaloustian K, Musick BS, Cornell M, Goodwin K, Addison D, Dusingize JC, Messou E, Poda A, Duda SN, McGowan CC, Law MG, Moore RD, Freeman A, Nash D, and **Wester CW**. Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. *Journal of the Int AIDS Soc*. 2017 Jan 6;20(1):1-14. doi: 10.7448/IAS.20.1.20933.PMID: 28364561.
60. Sarko KA, Blevins M, Ahonkhai AA, Audet CM, Moon TD, Gebi UI, Gana AM, **Wester CW**, Vermund SH, and Aliyu MH. HIV status disclosure, facility-based delivery, and postpartum retention of mothers in a prevention clinical trial in rural Nigeria. *Int Health*. 2017 Jul 1;9(4):243-251. doi: 10.1093/inthealth/ihx023. PMID: 28810669.
61. Erlandson KM, Kitch D, **Wester CW**, Kalayjian RC, Overton ET, Castillo-Mancilla J, Koletar SL, Benson CA, Campbell TB, Robertson K, Lok JJ. The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus Infection. *Clin Infect Dis*. 2017 November 29;65(12):2042-2049. doi: 10.1093/cid/cix645. PMID: 29020174.
62. Parcesepe A, Mugglin C, Nalugoda F, Bernard C, Yuniastuti E, Althoff K, Jaquet A, Haas AD, Duda SN, **Wester CW**, and Nash D, for the IeDEA Collaboration "Screening and management of mental health and substance use disorders in HIV treatment settings in low- and middle-income countries within the global IeDEA consortium." *J Int AIDS Soc*. 2018 Mar;21(3): e25101. doi: 10.1002/jia2.25101. PMID: 29603887.
63. Wahlfeld CC, Muicha A, Kipp AM, **Wester CW**, and Moon TD. HIV Rapid Diagnostic Test Inventories in Zambézia Province, Mozambique: A Tale of Two Test Kits. *Int J Health Policy Manag*. 2019 Feb 26;8(5):292-299. doi: 10.15171/ijhpm.2019.07.PMID: 31204445.
64. Bravo M, Peratikos MB, Muicha AS, Mahagaja E, Alvim MFS, Green AF, **Wester CW**, Vermund SH. Monitoring pharmacy and test kit stocks in rural Mozambique: U.S. PEPFAR Surveillance to help prevent Ministry of Health shortages. *AIDS Res Hum Retroviruses*. 2020 Jan 9. doi: 10.1089/AID.2019.0057. [Epub ahead of print]. PMID: 31914787.
65. Aliyu MH, Wudil UJ, Ingles DJ, Shepherd BE, Gong W, Musa BM, Muhammad H, Sani MU, Abdu A, Nalado AM, Atanda A, Ahonkhai AA, Ikizler TA, Winkler CA, Kopp JB, Kimmel PL, **Wester CW**. Optimal management of HIV-positive adults at risk for kidney disease in Nigeria (Renal Risk Reduction "R3" Trial): protocol and study design. *Trials*. 2019 Jun 10;20(1):341. doi: 10.1186/s13063-019-3436-y. PMC6558910.
66. Brazier E, Maruri F, Duda SN, Tymejczyk O, **Wester CW**, Somi G, Ross J, Freeman A, Davies M-A, Poda A, Kimmel A, Yotebieng M, and Nash D. Implementation of 'Treat-all' at adult HIV care and treatment sites in the Global IeDEA Collaboration: Results from the Site Assessment Survey. *J Int AIDS Soc*. 2019 Jul;22(7): e25331. doi: 10.1002/jia2.25331.PMID: 31623428.
67. Arinze F, Gong W, Green AF, De Schacht C, Carlucci JG, Silva W, Claquin G, Tique JA, Stefanutto M, Graves E, van Rompaey S, Alvim MFS, Tomo S, Moon TD, and **Wester CW**. Immunodeficiency at Antiretroviral Therapy Start: Five Year Adult Data (2012-2017) Based on Evolving National Policies in Rural Mozambique. *AIDS Res Hum Retroviruses*. 2020 Jan;36(1):39-47. doi: 10.1089/AID.2019.0043. Epub 2019 Sep 3. PMID: 31359762.
68. Calder CL, O'Hara H, Tabatabaia M, Maxwell CJ, Marryshow S, Ahonkhai AA, Audet CM, **Wester CW**, Aliyu MH. Adherence to Combination Antiretroviral Therapy among Pregnant Women Enrolled in a HIV Prevention Program in Rural North-central Nigeria. *Int J MCH AIDS*. 2020;9(1):81-92. doi: 10.21106/ijma.327. Epub 2020 Jan 12.
69. Boettiger DC, Law MG, Ross J, Huy BV, Heng B, Ditangco R, Kiertiburanakul S, Avihingsanon A, Cuong DD, Kumarasamy N, Kamarulzaman A, Ly PS, Yuniastuti E, Parwati Merati T, Zhang F, Khusuwan S, Chaiwarith R, Lee MP, Sangle S, Choi JY, Ku WW, Tanuma J, Ng OT, Sohn AH, **Wester CW**, Nash D, Mugglin C, Pujari S on behalf of International Epidemiology Databases to Evaluate AIDS - Asia-Pacific. Atherosclerotic cardiovascular disease screening and management practices among adult HIV clinics in Asia. *J Virus Erad*. 2020 Feb 20;6(1):11-18. PMID: 32175086.
70. Mulenga LB, Musonda P, Chirwa L, Siwingwa A, Suwilanji S, Mweemba A, Fwoloshi S, Phiri H, Phiri D, Mulenga PL, Chisenga T, Nsakanya R, Shibemba A, Todd J, Nzala S, Kaile T, Kankasa C, Gong W, Koethe JR, Hachaambwa L, Claassen C, Vinikoor M, Sikazwe I, Heimbürger DC, and **Wester CW**. Insulin Resistance is Associated with Higher

Plasma Viral Load Among HIV-Positive Adults Receiving Longer-Term (1 Year) Combination Antiretroviral Therapy (ART). *Journal of Infectious Disease & Therapy* 2019; 7:4.

71. Parcesepe A, Lancaster KE, De Boni R, Edelman JE, Ross J, Atwoli L, Tlali M, Althoff K, Tine J, Duda SN, Wester CW, and Nash D. Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014 and 2017. *PLOS ONE*. 2020 Aug 27;15(8): e0237772. doi: 10.1371/journal.pone.0237772. eCollection 2020. PMID: 32853246.
72. **Wester CW**, Jenkins CA, Koethe JR, Freeman A, Kalayjian R, Mendes A, Abraham AG, Lake JE, Erlandson K, Crane H, Sterling TR, Moore RD, and Shepherd BE. Association between angiotensin receptor blocker and angiotensin converting enzyme inhibitor exposure and all-cause mortality in HIV-positive adults. In preparation.
73. Limou S, Bussmann H, Novitsky V, Moyo S, Essex M, Marlink RG, Winkler CA, and **Wester CW**. Large-Scale Gene-Centric Exploration of Risk for NRTI/NNRTI-Associated Toxicities in Botswana. In preparation.
74. Limou S, Winkler CA, Bussmann H, Novitsky V, Moyo S, Essex M, Marlink RG, and **Wester CW**. *NEGR1* Genetic Variants and Risk for Virological Failure with Genotypic Resistance in Botswana. In preparation.
75. Wudil U, Mugglin C, Wandeler G, Duda S, Brazier E, Maruri F, Nash D, and **Wester CW**. Screening and treatment of Kidney and liver diseases at IeDEA HIV treatment sites in low- and middle-income countries. In preparation.
76. Mugglin C, Parcesepe A, Duda S, Brazier E, Maruri F, Nash D, and **Wester CW**. Screening and treatment of cardiovascular disease and diabetes mellitus at IeDEA HIV treatment sites in low- and middle-income countries. In preparation.
77. Van Rompaey S, Melo M, Viele JR, Green AF, Machabane H, Muicha A, Magumisse C, and **Wester CW**. Improving documentation of antiretroviral therapy (ART) medication pick-up via an electronic pharmacy barcode system in rural Mozambique. In preparation.
78. Rohner E, Mugglin C, Jaquet A, Merati T, Wools-Kaloustian K, Dzudie A, Moreira Jalil E, Bohlius J, Nash D, Egger M, and **Wester CW** on behalf of IeDEA. Cancer Prevention and Care among Women Living with HIV in Low- and Middle-Income Countries. In preparation.
79. Ahonkhai AA, Aliyu MH, Audet CM, Bravo M, Simmons M, Claquin G, Carlucci JG, Van Rompaey S, Gong W, Vermund SH, and **Wester CW**. Poor Retention and Care-Related Sex Disparities Among Youth Living with HIV in Rural Mozambique. Under review *PLOS ONE*.
80. Clark DE, Parikh A, Davogustto GE, Gayle KA, **Wester CW**, White KD, Soslow JH, Dendy JM, and Hughes SG. COVID-19 Multisystem Inflammatory Syndrome in an Adult (MIS-A) with Myopericarditis and Intracardiac Thrombosis. In preparation.
81. Wudil UJ, Aliyu MH, Ingles DJ, Ahonkhai AA, Musa BM, Muhammad H, Sani MU, Nalado AM, Abdu A, Abdussalam K, Shepherd BE, Prigmore HL, Dankishiya FS, Binns-Roemer E, Wyatt CM, Kopp JB, Kimmel PL, Winkler CA, and **Wester CW**. Apolipoprotein-1 (*APOL1*) risk variants and associated kidney phenotypes in an HIV cohort in Nigeria. In press. *Kidney International*.
82. **Wester CW**, Wudil UJ, Prigmore HL, Ingles DJ, Ahonkhai AA, Musa BM, Muhammad H, Sani MU, Nalado AM, Abdu A, Dankishiya FS, Abdussalam K, Shepherd BE, Burgner AM, Ikizler AT, Wyatt CM, Winkler CA, Kopp JB, Kimmel PL, and Aliyu MH. Factors Associated with Microalbuminuria Among HIV-positive, ART-treated Adults in Northern Nigeria. In preparation.
83. McMahon DE, Semeere A, Laker-Oketta M, Byakwaga H, Mugglin C, Duda SN, Azwa I, Jaquet A, Wagner Cardoso S, Nash D, **Wester CW**, and Freeman EE. Global disparities in skin cancer services at HIV treatment centers across 29 Countries. Accepted *Journal of Investigative Dermatology* (to be in press March 2021).
84. Ahonkhai AA, Wudil UJ, Dankishiya FS, Ingles DJ, Musa BM, Muhammad H; Sani MU, Nalado AM, Abdu A, Abdussalam K, Pierce L, **Wester CW**, and Aliyu MH. Implementation Strategies for Successful Clinical Trial Recruitment of People Living with HIV in Low- and Middle-Income Countries: Lessons from the Nigeria Renal Risk Reduction (R3) Trial. Submitted/under review (invited Supplement in *Current HIV/AIDS Reports*).
85. De Schacht C, Lucas C, Paulo P, Van Rompaey S, Fernando AN, Chinai JE, Chicuecue N, Silva WP, Amane G, Siteo N, Sultane T, Honwana N, Wei S, Malimane I, Couto A, and **Wester CW**. Pharmacy-based HIV self-testing is acceptable in Mozambique, but is an unassisted strategy sufficient? In preparation.
86. Mbalame PJA, Mhawila MA, José E, Yeung A, Tique JA, Ntasis E, Viele JR, Alvim MFS, **Wester CW**, Mutemba HA, Were MC. Development and Implementation of an mHealth-based Mentoring Application for Use in Resource

Constrained Settings. In preparation.

87. Carlucci JG, De Schacht C, Graves E, González P, Bravo M, Yu Z, Amorim GG, Arinze F, Silva W, Tique JA, Alvim MFS, Simione B, Fernando AN, and **Wester CW**. Immunodeficiency Among HIV-positive Children in the Setting of Evolving Antiretroviral Therapy Initiation Policies: 6 Years of Pediatric CD4 Data from Zambézia Province, Mozambique. Under review at *JAIDS*.
88. Aliyu MH, Sani MU, Ingles DJ, Tsiga-Ahmed FI, Musa BM, Audet CM, and **Wester CW**. The V-BRCH Project: building clinical trial research capacity for HIV and noncommunicable diseases in Nigeria. *Health Res Policy Sys* (2021) 19:32. <https://doi.org/10.1186/s12961-020-00656-z>.

Books and Textbook Chapters

89. **Wester CW**, Bussmann H. Recognition and Management of Antiretroviral Toxicities in Adults. In: Marlink RG, ed. *From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings* (Elizabeth Glaser Pediatric AIDS Foundation) in “Science and Treatment of HIV Infection” Section; 129-148 [Chapter].
90. Bussmann C, Ndwapi N, Gaolathe T, Bussmann H, **Wester CW**, et al. Supporting National ART Scale-Up in Botswana through Standardized, Multi-phased Training. In: Marlink RG, ed. *From the Ground Up: Building Comprehensive HIV/AIDS Care Programs in Resource-Limited Settings*. (Elizabeth Glaser Pediatric AIDS Foundation) in “Workforce Capacity” Section; 77-92 [Chapter].
91. **Wester CW**, Limou S, and Winkler CA. “HIV Pharmacogenetics and Pharmacogenomics”. In: “*Genomic and Personalized Medicine*”, 2nd Edition, Edited by GS Ginsburg and HF Willard, Elsevier Publishing. Chapter 117 [Review]; in press 2013; 1211-1230. ISBN: 978-0-12-382227-7 (set).
92. Stitelman OM, DeGruttola V, **Wester CW**, van der Laan M. Randomized Clinical Trials with Time-to-Event Outcomes and Effect Modification Parameters. In: van der Laan M and Rose S, ed. *Targeted Learning. Causal Inference for Observational and Experimental Data*. Springer Series in Statistics 2011, Chapter 18: 271-294 [Review].
93. **Wester CW**. Antiretroviral Medications, Adult Care, and Treatment. © Springer Science+Business Media LLC 2017 Thomas J. Hope, Douglas Richman, and Mario Stevenson (Editors). *Encyclopedia of AIDS*. 10.1007/978-1-4614-9610-6-166-1.
94. Limou S, Winkler CA, and **Wester CW**. “HIV pharmacogenetics and pharmacogenomics: From bench to bedside”. In: “*Genomic and Personalized Medicine*”, 3rd Edition, Edited by GS Ginsburg and HF Willard, Elsevier Publishing. Chapter 13 [Review]; in press 2019; 185-214. Genomic and Precision Medicine. <https://doi.org/10.1016/B978-0-12-801496-7.00013-7>. **NOTE:** We updated this chapter to include new developments in HIV Pharmacogenetics and Pharmacogenomics with special emphasis on Non-Communicable Diseases (NCDs) (at request of editorial staff).

Select Presentations at Scientific Meetings (past 5 years)

1. Lessons Learned from Capacity Building in Rural Mozambique: 2 Year Outcomes from Antiretroviral Therapy (ART) Scale-Up in Zambézia Province. Negrete M, Vallejo Torres J, Blevins M, Bravo M, Alvim F, Filimao DB, Silva W, Stefanutto M, Mahagaja E, Tique J, Viele J, Mutemba H, Green AF, Lankford J, Aliyu MH, Vermund SH, and **Wester CW**. XV Jornadas de Saúde (Mozambique Ministry of Health's 15th Annual National "Health Days" Conference), September 2015; Maputo, Mozambique.
2. Cumba L, Mahagaja E, Júnior A, Jaime P, Caliche H, Maitor D, Cugara C, Bravo M, **Wester CW**, and Filimão DB. A Highly Successful Massive Early Infant HIV Testing Campaign in rural Mozambique. Poster # 878. 8th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention; Vancouver, B.C.; July 19th-22nd, 2015.
3. Aliyu MH, Blevins M, Audet CM, Kalish M, Lindegren ML, Gebi UI, Onwujekwe O, Shepherd BE, **Wester CW**, and Vermund SH. Optimizing PMTCT Outcomes in Rural North-Central Nigeria: A Cluster-Randomized Study. Presented as oral abstract/themed discussion (Abstract # 790) at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA; February 22nd-25th, 2016.
4. Erlandson KM, Kitch D, **Wester CW**, Kalayjian R, Overton ET, Castillo-Mancilla JR, Koletar SL, Benson CA, Robertson KR, and Lok J. Statin or ACE/ARB effects on Neurocognitive Function of HIV-Infected Adults. Presented as poster (Poster # 421) at the 23rd Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA; February 22nd-25th, 2016.
5. Rutherford G, Kipp A, Lindegren ML, Shepherd BE, **Wester CW**, Nash D, Moore RD, Dabis F, Althoff K, Wools-Kaloustian K, and Yiannoutsos CT. Comparison of 48- and 96-week outcomes in adults initiating tenofovir + lamivudine/emtricitabine + efavirenz and those initiating two other nucleoside reverse transcriptase inhibitors + efavirenz using propensity-score matched IeDEA observational cohort data and data from randomised controlled trials. Abstract # 33 (oral presentation). Proceedings of the 20th International Workshop on HIV Observational Databases. Budapest, Hungary; April 2016. (Oral Abstract presentation— April 7th-9th, 2016).
6. Vreeman RC, Lindegren ML, **Wester CW**, Blevins M, Sohn AH, Davis MA, Edmonds A, Quinn CF, Nwosu S, Wools-Kaloustian K, Leroy V, McGowan C, and Vinikoor MJ for the IeDEA Consortium. Trends in Global Pediatric HIV Programmatic Capacity among Sites of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Consortium. Abstract # B87. Proceedings of the 21st International AIDS Society (IAS) conference. Durban, South Africa; July 2016. (Poster presentation).
7. Rutherford GW, Lindegren ML, Kipp A, Shepherd BE, **Wester CW**, et al. Comparison of 48- and 96-week outcomes in HIV-infected adults initiating tenofovir + lamivudine/emtricitabine + efavirenz and those initiating two other nucleoside reverse transcriptase inhibitors + efavirenz using meta-analysis by IeDEA region compared to randomized controlled trials. 20th Annual Workshop on HIV Observational Databases; Lisbon, Portugal; March 30-April 1, 2017 (Oral abstract presentation).
8. Mugglin C, Egger M, Urassa M, Pujari S, Jaquet A, Duda SN, Keiser O, Nash D, and **Wester CW** for the IeDEA Collaboration. HIV care and treatment sites' capacity to manage NCDs: Diabetes and Hypertension. 20th Annual Workshop on HIV Observational Databases; Lisbon, Portugal; March 30 - April 1, 2017 (Poster).
9. Rutherford GW, Lindegren ML, Kipp A, Shepherd BE, **Wester CW**, Nash D, Moore RD, Dabis F, Althoff K, M Egger, Wools-Kaloustian K and Yiannoutsos CT, for the IeDEA Consortium. Can WHO guidelines use observational data? An empirical comparison of three methods for adjusting observational data and a meta-analysis of randomized controlled trials. 9th International AIDS Society HIV Science, Paris, France; July 23 – 26, 2017 (Poster).
10. Parcesepe A, Mugglin C, Egger M, Nalugoda F, Bernard C, Yunihastuti E, Duda SN, **Wester CW**, Nash D, for the IeDEA Collaboration. Capacity to screen and treat mental health and substance use disorders at HIV treatment sites in low- and middle-income countries. 9th International AIDS Society HIV Science, Paris, France; July 23-26, 2017 (Poster).
11. Mugglin C, Mulenga L, Mweemba A, Wyatt C, Abo Y, Avihingsanon A, Wools-Kaloustian K, McGowan C, Nash D, Egger M, and **Wester CW**. Site capacity to screen for and manage renal dysfunction among HIV-infected persons receiving care in low- and middle-income countries (LMICs). 9th International AIDS Society HIV Science (IAS 2017), Paris, France; July 23-26, 2017 (Poster).

13. Melo M, Viele JR, Green AF, Machabane H, Muicha Am, Magumisse C, and **Wester CW**. Improving documentation of antiretroviral therapy (ART) medication pick-up via electronic pharmacy barcode system in rural Mozambique. 9th IAS Conference on HIV Science (IAS 2017); Paris, France. July 23-26, 2017 (Poster).
14. Aliyu MH, Audet CM, Simmons M, Claquin G, Bilhete F, Vermund SH, and **Wester CW**. Poor Retention and Care-Related Sex Disparities Among Youth Living with HIV in Rural Mozambique. 9th IAS Conference on HIV Science (IAS 2017); Paris, France. July 23-26, 2017 (Poster).
15. Mulenga LB, Chirwa L, Mweemba A, Phiri H, Nsakanya R, Moyo C, Mwango A, Phiri D, Suwilanji S, Mulwanda J, Todd J, Nzala S, **Wester CW**, Heimbürger DC, Duber H, Kankasa C. 12 months virological outcomes among HIV-1-Infected patients initiated on first-line combination antiretroviral therapy in the Zambian national ART program. 9th IAS Conference on HIV Science (IAS 2017); Paris, France. July 23-26, 2017 (Poster).
16. Rohner E, Mugglin C, Jaquet A, Merati T, Wools-Kaloustian K, Dzudie A, Moreira Jalil E, Bohlius J, Nash D, Egger M, and **Wester CW** on behalf of IeDEA. "Cancer Prevention and Care in HIV-Positive Women in Low- and Middle-Income Countries". 21st Annual Workshop on HIV Observational Databases; Fuengirola, Spain; March 22 - March 24, 2018 (Poster).
17. Brazier E, Maruri F, Duda SN, Tymejczyk O, **Wester CW**, Somi G, Ross J, Freeman A, Davies M-A, Poda A, Kimmel A, Yotebieng M, and Nash D for the IeDEA Collaboration. "Implementation of 'Treat-All' at sites participating in the Global IeDEA Collaboration – Results from the 2017 survey of HIV treatment sites in 44 countries, 2017." 21st Annual Workshop on HIV Observational Databases; Fuengirola, Spain; March 22 - March 24, 2018 (Poster).
18. Melo M, DeSchacht C, Langa J, Pinto R, Inácio A, Silva W, Stefanutto M, Gonzalez P, Cowan JG, **Wester CW**, Van Rompaey S. Implementing a Quality Improvement Initiative in a Large HIV Clinic to Improve the Availability of Pediatric Viral Load Results in Rural Mozambique. 10th IAS Conference on HIV Science (IAS 2019); Mexico City, Mexico. July 21-24, 2019 (Poster).
19. Mayra M, DeSchacht C, Ntasis E, Tique JA, Matsimbe J, Claquin G, Alvim MFS, Jose E, Mutemba HA, Inácio A, Fernando AN, Amorim G, **Wester CW**, and Van Rompaey S. Improved 12-Month ART Retention Rates Through Intensive Monitoring of Key Process Measures in Zambezia Province, Mozambique. 10th IAS Conference on HIV Science (IAS 2019); Mexico City, Mexico. July 21-24, 2019 (Poster).
20. Graves E, DeSchacht C, Gong W, Van Rompaey S, Alvim MFS, Claquin G, Shepherd BE, Green AF, Tique JA, Jose E, Machabane H, Maposse E, Bravo M, Fernando AN, and **Wester CW**. Effectiveness of Short Message Service (SMS) Reminders on Timely Pick-Up of Antiretroviral Therapy (ART) Among Consenting HIV-Positive Adults in Zambezia Province, Mozambique. 10th IAS Conference on HIV Science (IAS 2019); Mexico City, Mexico. July 21-24, 2019 (Poster).
21. Moiane S, Mbalame P, Mhawila MA, Jose E, Yeung A, Tique JA, Ntasis E, Viele JR, Alvim MFS, Mutemba HA, **Wester CW**, and Were MC. Development and Implementation of an mHealth-based Mentoring Application for Use in Low-Resource Settings. Pan-African health informatics conference (HELINA), Gaborone, Botswana. November 20-22, 2019 (Oral Presentation).
22. DeSchacht C, Lucas C, Paulo P, Chinai JE, Fernando AN, Chicucue N, Silva W, Viegas S, Van Rompaey S, Couto A, and **Wester CW**. HIV Self-Testing is Acceptable in Mozambique, But Is an Unassisted Strategy Sufficient? 27th Conference on Retroviruses and Opportunistic Infections (CROI); Boston, MA. March 8-11, 2020 (Poster).
23. Carlucci JG, DeSchacht C, Graves E, González P, Bravo M, Prigmore H, Amorim G, Arinze F, Silva W, Tique JA, Alvim MFS, Simone B, Fernando AN, and **Wester CW**. Immunodeficiency among HIV-Positive Children in the Setting of Evolving Antiretroviral Therapy Initiation Policies: 5 Years of Pediatric CD4 Data from Zambézia Province, Mozambique. December 1-4, 2020, INTEREST 2020 conference, Windhoek, Namibia (Poster).
24. DeSchacht C, Amorim G, Calvo L, Kassim H, Carlos IC, Matsimbe J, Martinho S, Graves E, Van Rompaey S, Ntasis E, **Wester CW**, and Audet CM. For each Hour a Patient Living with HIV Spends in the Health Facility, the Probability of Being Retained in Care Decreases: Results from a Patients' Satisfaction Survey in Mozambique. To be presented December 1-4, 2020, INTEREST 2020 conference, Windhoek, Namibia (Poster).
25. DeSchacht C, Ntasis E, Calvo L, Matsimbe J, Martinho S, Graves E, Kassim H, Carlos IC, **Wester CW**, Van Rompaey S, Amorim G, and Audet CM. Interpersonal Patient Satisfaction Factors More Strongly Correlated with Retention in Care than Structural Factors Among Adults Receiving HIV Services in Rural Mozambique. July 6-10, 2020, AIDS 2020 conference, Oakland, CA (Virtual Poster).
26. DeSchacht C, Amorim G, Van Rompaey S, Matsimbe J, Fernando AN, Tique JA, Torres I, Dique L, Ntasis E, and **Wester**

CW. Positive Effects of Intensified Preventive Calls/Home Visits on early Retention Among Adults Newly Initiated on Antiretroviral Therapy in Zambezia Province, Mozambique. December 1-4, 2020, INTEREST 2020 conference, Windhoek, Namibia (Mini Oral Presentation).

27. Van Rompaey S, Pinto R, Tique JA, Tadeu B, Cabsela C, Fataha J, Inácio A, Silva W, Matsimbe J, Gonzalez P, Cowan JG, Nguimfack A, DeSchacht C, and **Wester CW.** Evidence of a Quality Improvement-Guided Intervention to Improve the Availability of Viral Load Results Among Pregnant and Lactating Women Receiving Care at a Large HIV Clinic in Rural Zambézia, Mozambique. December 1-4, 2020, INTEREST 2020 conference, Windhoek, Namibia (Poster).